Pharmacometabolomics in TB Meningitis – understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid

Jeffrey M. Collins¹, Maia Kipiani^{2,3,4}, Yutong Jin⁵, Ashish A. Sharma⁶, Jeffrey A. Tomalka⁶, Teona Avaliani², Mariam Gujabidze², Tinatin Bakuradze², Shorena Sabanadze², Zaza Avaliani^{2,7}, Henry M. Blumberg^{1,8}, David Benkeser⁵, Dean P. Jones¹, Charles Peloquin⁹, Russell R. Kempker¹.

¹Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

²National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

³The University of Georgia, Tbilisi, Georgia

⁴David Tvildiani Medical University, The University of Georgia, Tbilisi, Georgia National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

⁵Department of Biostatistics, Rollins School of Public Health of Emory University, Atlanta, Georgia, USA

⁶Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

⁷European University, Tbilisi, Georgia

⁸Departments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

⁹Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.

* Correspondence:

Name: Jeffrey Collins, MD, MPH, MSc Email: jeffrey.michael.collins@emory.edu Keywords: tuberculosis, meningitis, metabolomics, cytokines, CSF Running Title: Pharmacometabolomics in TB Meningitis Article Type: Research Article

1 Abstract

2 Poor penetration of many anti-tuberculosis (TB) antibiotics into the central nervous system (CNS) is thought to be a major driver of morbidity and mortality in TB meningitis 3 4 (TBM). While the amount of a particular drug that crosses into the cerebrospinal fluid 5 (CSF) varies from person to person, little is known about the host factors associated with interindividual differences in CSF concentrations of anti-TB drugs. In patients 6 diagnosed with TBM from the country of Georgia (n=17), we investigate the association 7 between CSF concentrations of anti-TB antibiotics and multiple host factors including 8 9 serum drug concentrations and CSF concentrations of metabolites and cytokines. We found >2-fold differences in CSF concentrations of anti-TB antibiotics from person to 10 person for all drugs tested including cycloserine, ethambutol, imipenem, isoniazid, 11 12 levofloxacin, linezolid, moxifloxacin pyrazinamide, and rifampin. While serum drug concentrations explained over 40% of the variation in CSF drug concentrations for 13 cycloserine, isoniazid, linezolid, and pyrazinamide (adjusted $R^2 > 0.4$, p<0.001 for all), 14 there was no evidence of an association between serum concentrations of imipenem 15 and ethambutol and their respective CSF concentrations. CSF concentrations of 16 17 carnitines were significantly associated with concentrations of ethambutol and imipenem (q<0.05), and imipenem was the only antibiotic significantly associated with CSF 18 cytokine concentrations. These results indicate that there is high interindividual 19 20 variability in CSF drug concentrations in patients treated for TBM, which is only partially explained by differences in serum drug concentrations and not associated with 21 22 concentrations of cytokines and chemokines in the CSF.

23

24 Introduction

Tuberculosis meningitis (TBM) is the most lethal manifestation of tuberculosis 25 26 (TB) disease, with a mortality rate $\geq 25\%$ in those with drug susceptible disease and >65% in persons with drug resistance.^{1,2} Therapeutic options for TBM are more limited 27 28 than in other forms of TB due to poor penetration of many anti-TB drugs into the central nervous system (CNS).^{1,3-5} However, the concentration of antibiotics in the CNS can 29 30 vary widely by antibiotic and from person to person, indicating certain endotypes exist 31 that lead to favorable CNS penetration of drugs. While it is generally thought that 32 meningeal inflammation increases the CNS concentration of antibiotics, there is limited empirical evidence supporting this concept in TBM.⁶ Further, little is known about the 33 34 specific inflammatory signaling networks in TBM that may modulate CNS penetration of anti-TB chemotherapeutic agents. An improved understanding of host responses 35 associated with CNS penetration of anti-TB drugs could help inform new strategies to 36 37 enhance drug delivery to the site of disease in TBM.

Recent advances in metabolomics and high-density cytokine measurement allow 38 for high-resolution immunometabolic profiling of a variety of human samples including 39 cerebrospinal fluid (CSF).⁷ Such profiling allows for simultaneous measurement of over 40 30 cytokines and thousands of metabolites, including xenobiotics⁸ and molecules that 41 regulate inflammation.^{9,10} Combining measurement of these host response molecules 42 43 with drug concentrations at the site of disease has the potential to elucidate metabolic 44 and inflammatory processes that regulate drug concentrations and efficacy in TBM; an approach termed pharmacometabolomics.¹¹ 45

46 In a well characterized population of patients from the country of Georgia diagnosed and treated for TBM, we integrated data on serum and CSF concentrations 47 of anti-TB antibiotics⁵ and CSF concentrations of metabolites and cytokines.⁷ By 48 49 integrating these data sets, we sought to address multiple knowledge gaps that currently exist with regard to antibiotic therapy for TB meningitis as follows: 1) the 50 degree of interindividual variability in CSF drug concentrations, 2) whether variation in 51 serum drug concentrations explain the variation in CSF drug concentrations, 3) whether 52 untargeted metabolomics can be used to accurately measure concentrations of TB 53 54 antibiotics in the CNS, and 4) whether individual differences in the CSF milieu of soluble immunometabolic mediators (i.e. metabolites and cytokines) are associated with CSF 55 drug concentrations of different anti-TB drugs. 56

57 **RESULTS**

58 **Participants**

59 We studied CSF samples from 17 participants with suspected TBM presenting to the National Center for Tuberculosis and Lung Diseases (NCTLD) (Table 1). Among the 60 17 patients with suspected TBM, five (29%) were microbiologically confirmed while 61 three (18%) were considered to have probable TBM and nine (53%) were considered to 62 have possible TBM based on clinical and laboratory criteria.^{12,13} The median CSF white 63 blood cell (WBC) count at diagnosis was 209 cells/mm³ (IQR 130-286), with 94% 64 65 lymphocytes (IQR 85-96), a median glucose of 40 mg/dL (IQR 21-50), and total protein of 99 mg/dL (IQR 66-132). Antibiotic regimens were selected by treating clinicians 66 based on NCTLD guidelines and response to treatment as previously reported.^{5,14} Five 67 68 persons with TBM were deemed to have a poor initial response to treatment, two of

69 whom were diagnosed with multi-drug-resistant (MDR)-TBM based on microbiologic

70 testing.

71 Variation in CSF Concentrations of Anti-TB Drugs

72 We first sought to characterize the interindividual variability of anti-TB drug 73 concentrations in the CSF. As per standard of care for patients hospitalized with TBM at NCTLD, lumbar punctures were performed at diagnosis (baseline) and approximately 7, 74 14, and 28 days after TBM treatment initiation and monthly for as long as patients were 75 hospitalized to follow CSF cell and protein counts in response to treatment.^{5,14} Due to 76 77 differences between participants in the number of antibiotic doses received at the time of the baseline CSF sample, only samples obtained \geq 7 days after treatment start were 78 79 included in this analysis. Antibiotic concentrations were quantified in the serum and CSF at each time point either 2 or 6 hours after the most recent antibiotic dose as previously 80 described.⁵ A 2- to 4-fold difference in CSF drug concentrations was found between 81 82 participants at 2 hours (Figure 1A-I) and 6 hours (Figure 2A-I) after the dosing of anti-83 TB antibiotics. This was observed across antibiotics, indicating a large amount of interindividual variability in CSF drug concentrations regardless of the drug used. 84 85 There are multiple sources of potential interindividual variability in CSF drug concentrations among patients with TBM including integrity of the blood-brain and 86 blood-CSF barriers, variability in protein binding, and differential expression of drug 87 transporters.¹⁵ TB drugs are also known to have large differences in serum 88 concentration from person to person, which could explain some or all of the variability in 89 CSF drug concentrations.¹⁶ To examine this possibility, we sought to determine how 90

91 well concomitantly collected serum drug concentrations explained the variation in CSF

92 drug concentrations using a mixed effects linear model. We found the relationship 93 between plasma and CSF drug concentrations varied substantially from drug to drug. For cycloserine, isoniazid, and linezolid, we calculated an adjusted R^2 of >0.5. 94 95 suggesting serum drug concentrations explained over 50% of the variability in CSF drug 96 concentrations (Figure 3A-C). For other drugs including pyrazinamide, levofloxacin, and 97 rifampin, serum drug concentrations explained a statistically significant amount of variation in CSF concentrations, but the adjusted R² values were 0.4, 0.23 and 0.19 98 respectively (Figure 3D-F). For moxifloxacin, imipenem, and ethambutol, serum drug 99 100 concentrations were not significantly associated with CSF drug concentrations (Figure 3G-I). 101

102 Using Untargeted Metabolomics to measure CSF Drug Concentrations

103 We performed untargeted high-resolution metabolomics on CSF samples using combined liquid chromatography-mass spectrometry in dual ionization mode with HILIC 104 105 positive and c18 negative chromatography (see Methods for full details). We detected 106 6,596 metabolic features in positive ionization mode and 9,427 in negative ionization 107 mode. We then performed a targeted search for molecular features that were within a 108 mass and retention time error range of 5 ppm and 30 seconds respectively for the M+H 109 or M-H adducts of anti-TB drugs. This query yielded high confidence matches for 110 several anti-TB drugs including ethambutol, isoniazid, pyrazinamide, rifampin, linezolid, 111 imipenem, levofloxacin, and moxifloxacin. We then performed a correlation analysis of 112 the peak intensity for each annotated metabolite and the antibiotic concentration as measured using MS/MS and a purified standard curve.⁵ We found that the intensity 113 114 value for each antibiotic as measured by our untargeted metabolomics platform was

115 strongly correlated with the absolute concentration of most anti-TB antibiotics in the 116 CSF. Peaks for ethambutol, pyrazinamide, isoniazid, linezolid, and imipenem all demonstrated a Pearson correlation coefficient of >0.7 when compared with absolute 117 118 drug concentrations (Figure 4A-E; p<0.001 for all). The peak intensity for moxifloxacin 119 (r=0.53, p=0.05) and levofloxacin (r=0.45, p<0.001), as well as rifampin (r=0.48, p<0.001). 120 p<0.001), were also significantly correlated with measured CSF concentrations, but the 121 relationship was less strong than for the other antibiotics studied (Figure 4F-H). In the 122 case of rifampin, this may have been due in part to the relatively low concentration of 123 this antibiotic in the CSF. These data indicate that untargeted metabolomics can be an 124 effective method to approximate many anti-TB drug concentrations in biofluids. **Relationship Between CSF Metabolism, Inflammation, and Drug Concentrations** 125 126 Antibiotic penetration into the CSF is generally thought to be increased when there is a breakdown in the blood-brain barrier due to meningeal inflammation in 127 persons with TBM.¹⁷ We therefore sought to mine concomitantly collected high-128 129 resolution metabolomics and cytokine data to determine whether any soluble immune 130 mediators were associated with CSF drug concentrations. We used mixed effects linear 131 models to determine which cytokines and metabolites with known chemical identities were most strongly associated with CSF concentrations of each antibiotic. In Figure 5, 132 we show the metabolites and cytokines significantly associated with the concentration of 133 134 at least one antibiotic using a false discovery correction of q<0.05. We found that carnitines were significantly associated with CSF concentrations of ethambutol and 135 imipenem at q<0.05, as well as isoniazid, linezolid, pyrazinamide, and rifampin at an 136 137 unadjusted p<0.05. However, the directionality of the association was inconsistent.

While increased CSF concentrations of carnitines were associated with increased
concentrations of ethambutol and imipenem, they were associated with lower CSF
concentrations of isoniazid, linezolid, pyrazinamide, and rifampin. This suggests that
different metabolic states in the CNS may be associated with increased drug
penetration for certain classes of antibiotics while decreasing CSF drug concentrations
for others.
There were few significant associations between cytokine and antibiotic

concentrations in the CNS. Increased concentrations of pro-inflammatory cytokines and

146 chemokines including TNF-a, MCP-3, IL-6, IL-18, and IFN-y were associated with

147 increased concentrations of imipenem, but otherwise had little relationship to CSF

148 antibiotic concentrations. The only exception was IL-6, which was significantly

associated with CSF ethambutol concentrations. These data indicate that an

150 inflammatory CSF milieu had minimal impact on CSF concentrations anti-TB antibiotics.

151

152 **DISCUSSION**

In this TBM pharmacometabolomics study, we show there is significant 153 154 interindividual variability in CSF concentrations of anti-TB antibiotics. We further show that differences in serum drug concentrations account for much of the variability in CSF 155 concentrations of linezolid, isoniazid, and cycloserine, but have a less strong 156 157 relationship with CSF concentrations of imipenem, rifampin, moxifloxacin, and ethambutol. Finally, we demonstrate that CSF drug concentrations may be affected by 158 the CSF metabolic milieu and have little association with concentrations of 159 160 proinflammatory cytokines and chemokines. Together, these data show that a complex mix of factors contribute to CSF concentrations of anti-TB antibiotics. For many
antibiotics, factors such as CNS inflammation and serum concentrations, which are
traditionally thought to be primary drivers of drug concentrations in the CNS, may play
only a minor role.

While serum concentrations of anti-TB drugs are known to vary widely from 165 person to person.¹⁶ we show equally wide variability in CSF drug concentrations in 166 those treated for TBM. Across the study population we found greater than 2-fold 167 168 differences in CSF concentrations of all anti-TB drugs studied. This was true both two and six hours after the dose of each drug. Such variability in the CSF concentrations of 169 anti-TB drugs has been shown in other studies, most notably among 237 patients (>700 170 CSF samples) included in a pharmacology sub study evaluating rifampin, isoniazid, and 171 levofloxacin CSF concentrations.¹⁸ The substantial variation in CSF concentrations 172 173 among study participants was evidenced by large 95% confidence intervals for both C_{max} and AUC parameters.¹⁸ Furthermore, interpatient variability in CSF rifampin¹⁹ and 174 fluoroguinolone²⁰ concentrations have been demonstrated in clinical trial dose finding 175 176 and drug comparison studies, respectively. What has been less studied, is clinical or laboratory predictors of CSF drug concentrations. We found that serum concentrations 177 are poorly predictive of CSF concentrations for many drugs including imipenem, 178 179 rifampin, moxifloxacin, and ethambutol. Using the plasma rifampin AUC₀₋₂₄ parameter, 180 Dian et al, found a high correlation between plasma and CSF rifampin concentrations (Spearman's p 0.7, p<.01).¹⁹ A better understanding of predictors of CSF drug 181 penetration is needed to help both understand the underlying mechanisms of drugs 182

reaching the site of disease and also to identify clinically useful markers to help guideoptimal drug doing in TBM.

This study provides evidence that untargeted, high-resolution metabolomics can 185 186 be an accurate way to capture drug concentrations of multiple anti-TB drugs including 187 imipenem, ethambutol, isoniazid, linezolid, and pyrazinamide. This result is supported 188 by studies showing untargeted metabolomics can also be an accurate way to capture exposure to xenobiotics in the environment.⁸ The ability to accurately quantify drug 189 concentrations as part of an untargeted metabolomics platform is likely to create 190 191 additional opportunities to understand drug concentrations and pharmacokinetics in the 192 context of broader measurement of host metabolism. Understanding broad host 193 metabolic responses to drugs, termed "pharmacometabolomics", is an emerging area of 194 study with great potential to improve our understanding of heterogenous host responses to medications including antibiotics and enhance personalized medicine.¹¹ However, a 195 196 limitation of the approach has been the need to separately perform targeted 197 guantification of drugs and untargeted metabolomics. Our findings suggest that in many 198 cases, important insights in pharmacometabolomics could be obtained from untargeted 199 metabolomics data alone.

By simultaneously collecting pharmacology, metabolomics, and cytokine data in the present study, we were able to examine which soluble immune and metabolic mediators in CSF are associated with improved CNS penetration of TB drugs. The association between CSF concentrations of multiple antibiotics and carnitines suggests that a metabolic milieu with increased oxidative phosphorylation may impact antibiotic penetration in the CNS. Increased carnitines in the CSF, which transport fatty acids

206 from the cytosol into mitochondria to be oxidized, may reflect improved cellular function 207 and lower levels of glycolysis, which tends to produce greater inflammatory signaling in immune cells.^{9,21,22} Historically, greater inflammation in the CNS has been thought to be 208 a catalyst for drug penetration across blood-brain and blood-CSF barriers.¹⁷ The 209 210 present study found little relationship between CSF drug concentrations and proinflammatory cytokines. While elevated CSF concentrations of cytokines does not 211 212 necessarily indicate increased meningeal inflammation, the findings do suggest that the relationship between CSF drug concentrations and inflammation is minimal. This is 213 supported by prior work from our group, which indicated CSF concentrations of anti-TB 214 215 drugs are roughly equal early in the course TBM treatment versus two or more months after treatment start, when meningeal inflammation would be expected to decrease.⁵ 216 217 However, another explanation for these findings is that the CSF milieu remains highly inflammatory months after treatment start,⁷ which could mean CNS drug penetration is 218 219 enhanced for an extended period of time.

220 This study is subject to several limitations. The small sample size of persons with 221 TBM and low number of microbiologically confirmed cases from a single geographic 222 region available for analysis in this study may limit generalizability. Further, the 223 robustness of statistical inferences from such a small sample is limited. Though we demonstrate a strong association between CSF concentrations of multiple metabolites 224 225 and concentrations of anti-TB drugs, the observational nature of the study precludes us 226 from establishing a causal relationship. In future studies it will be important to evaluate the links between key metabolites and CSF drug penetration using animal models of 227 228 TBM and larger, diverse human cohorts. Enhancing our understanding of how soluble

229 mediators in the CNS impact drug penetration may lead to therapies that enhance drug 230 delivery to this area or personalized dosing regimens for individual patients. 231 Overall, this study shows the interindividual variation in CSF drug concentrations 232 among persons with TBM is high and potentially linked to the metabolic milieu of the 233 CSF. Serum drug concentrations are only weakly associated with CSF concentrations 234 for some drugs, and the amount of inflammation in the CSF appears to have only a 235 minor role in enhancing drug penetration. Our results provide insight into the factors that impact CSF drug concentrations in TBM and indicate that improved understanding of 236 237 the host metabolic response could provide targets to enhance drug delivery. 238 MATERIAL AND METHODS 239 240 Setting and Participants with TBM Persons with TBM were enrolled from the National Center for Tuberculosis and 241 242 Lung Diseases (NCTLD) in Tbilisi, Georgia as part of a clinical pharmacology study evaluating the penetration of anti-TB drugs into the CNS.⁵ Patients aged ≥ 16 years 243 244 treated in the NCTLD adult TBM ward from January 2018 to December 2019 were 245 eligible for inclusion. All patients suspected of having TBM underwent a lumbar puncture; acid-fast bacilli (AFB) staining, liquid and solid culture, and Xpert MTB/RIF 246 247 assay were performed on CSF. As per standard of care for patients hospitalized with 248 TBM at NCTLD, lumbar punctures were performed at approximately 7, 14, and 28 days 249 after TBM treatment initiation and monthly for as long as patients were hospitalized to follow CSF cell and protein counts in response to treatment.^{5,14} Treatment regimens 250 251 were selected by treating clinicians based on treatment history, comorbidities, and drug

susceptibility results when available.¹⁴ All patients also received a 6–8-week course of
dexamethasone (400-1200 mg). Written informed consent was obtained from all study
participants, and study approval was obtained from the institutional review boards of

255 Emory University and the NCTLD.

256 Sample Collection and Drug Quantification

257 Blood samples were collected at 2 and 6 hours after drug administration at each 258 timepoint. For CSF collection, 3 mL was collected at each time point, alternating 259 between 2 and 6 hours after drug administration to capture early and delayed drug penetration into the CSF. All centrifuged blood as well as CSF samples were stored at -260 261 80°C at the NCTLD until shipped to the Infectious Diseases Pharmacokinetic Laboratory at the University of Florida, where drug concentrations were quantified. Total 262 concentrations of each drug were measured using validated liquid chromatography 263 264 tandem mass spectrometry assays. The assays were validated for human plasma, and 265 cross checked for matrix effects using artificial CSF. The analyses were performed on Thermo Scientific TSQ Endura or TSQ Quantum Ultra mass spectrometers. 266

267 Metabolomics analysis

268 De-identified CSF samples were randomized by a computer-generated list into 269 blocks of 40 samples prior to transfer to the analytical laboratory where personnel were 270 blinded to clinical and demographic data. Thawed CSF (65 μ L) was treated with 130 μ l 271 acetonitrile (2:1, v/v) containing an internal isotopic standard mixture (3.5 μ L/sample), 272 as previously described.²³ Samples were centrifuged and supernatants were analyzed 273 using an Orbitrap Q Exactive Mass Spectrometer (Thermo Scientific, San Jose, CA, 274 USA) with dual HILIC positive and c18 negative liquid chromatography (Higgins Analytical, Targa, Mountain View, CA, USA, 2.1 x 10 cm) with a formic acid/acetonitrile gradient. The high-resolution mass spectrometer was operated over a scan range of 85 to 1275 mass/charge (m/z).²⁴ Data were extracted and aligned using apLCMS ²⁵ and xMSanalyzer ²⁶ with each feature defined by specific m/z value, retention time, and integrated ion intensity.²⁴ Three technical replicates were performed for each CSF sample and intensity values were median summarized.

281 Cytokine detection

The commercially available U-PLEX assay by Meso Scale Discovery (MSD) was 282 used for CSF cytokine detection. This assay allows for the evaluation of multiplexed 283 biomarkers by using custom made U-PLEX sandwich antibodies with a SULFO-TAG 284 conjugated antibody and electrochemiluminescence (ECL) detection. Direct quantitation 285 286 of cytokines was performed using standard curves generated by 4-fold serial dilutions of standard calibrators provided by MSD. Plates were read on the QuickPlex SQ 120 using 287 Methodical MindTM software and plate data analyzed using Discovery WorkbenchTM 288 software (MSD). 27,28 289

290 Statistical Analysis

291 Descriptive statistics were provided for baseline characteristics, and the 292 concentrations of anti-TB antibiotics in patients' CSF were summarized for each drug at 293 both 2-hour and 6-hour time points following the most recent antibiotic dose. We applied 294 a linear mixed regression model, adjusting for sampling time (2 or 6 hours),²⁷ and 295 reported the adjusted R-squared values of each pairwise comparison of models, 296 whether they included or excluded serum concentration²⁹. Similarly, to determine 297 associations between CSF drug concentrations and metabolite and cytokine

298	concentrations, we applied a linear mixed regression model, adjusting for sampling time
299	(2 or 6 hours), and reported the adjusted R-squared values of each pairwise
300	comparison of models, whether they included or excluded the concentration of a
301	particular metabolite or cytokine ²⁹ . A false discovery rate (FDR) correction was
302	employed to account for multiple comparisons when examining associations between
303	anti-TB drugs and metabolites and cytokines. 28 All analyses were conducted using R
304	version 4.2.1.

305

306 Acknowledgments

The authors thank the physicians, nurses, and staff at the NCTLD in Tbilisi, Georgia, who provided care for the patients with TBM included in this study. Additionally, the authors are thankful for study participants with tuberculosis meningitis who were willing to participate in the study and help contribute meaningful data that may help future patients with the same illness.

312

313 Conflict of Interest

314 The authors declare that the research was conducted in the absence of any commercial

or financial relationships that could be construed as a potential conflict of interest.

316

317 Funding

318 This work was supported by grants from the National Institutes of Health (NIH) and

National Institute of Allergy and Infectious Diseases [R03AI139871, K23AI103044,

320	K23AI144040, P30AI168386, P30AI050409]; NIH Fogarty International Center
321	[D43TW007124]; and NIH National Center for Advancing Translational Science
322	[UL1TR002378], Bethesda, MD, USA. The study sponsors had no role in the study
323	design; in the collection, analysis, and interpretation of data; in the writing of the
324	manuscript; or in the decision to submit the manuscript for publication.
325	
326	
327	
328	
329	
330	
331	
332	
333	
334	
335	
336	
337	
338	
339	
340	
341	
342	

343 References

- 1. Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol.
- 345 2017;13(10):581-598.
- 346 2. Evans EE, Avaliani T, Gujabidze M, et al. Long term outcomes of patients with
- tuberculous meningitis: The impact of drug resistance. PLoS One.
- 348 2022;17(6):e0270201.
- 349 3. Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical Outcomes of Patients With
- 350 Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis
- 351 Regimen. Clin Infect Dis. 2017;65(1):20-28.
- 4. Vinnard C, King L, Munsiff S, et al. Long-term Mortality of Patients With Tuberculous
- 353 Meningitis in New York City: A Cohort Study. Clin Infect Dis. 2017;64(4):401-407.
- 354 5. Kempker RR, Smith AGC, Avaliani T, et al. Cycloserine and Linezolid for
- 355 Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness. Clin Infect
- 356 Dis. 2022;75(4):682-689.
- 357 6. Nau R, Seele J, Djukic M, Eiffert H. Pharmacokinetics and pharmacodynamics of
- antibiotics in central nervous system infections. Curr Opin Infect Dis. 2018;31(1):57-68.
- 359 7. Tomalka J, Sharma A, Smith AGC, et al. Combined cerebrospinal fluid metabolomic
- 360 and cytokine profiling in tuberculosis meningitis reveals robust and prolonged changes
- in immunometabolic networks. Tuberculosis. 2023. *In press*.
- 362 8. Liu KH, Lee CM, Singer G, et al. Large scale enzyme based xenobiotic identification
 363 for exposomics. Nat Commun. 2021;12(1):5418.
- 364 9. Collins JM, Jones DP, Sharma A, et al. TCA cycle remodeling drives proinflammatory
- signaling in humans with pulmonary tuberculosis. PLoS Pathog. 2021;17(9):e1009941.

- 10. Collins JM, Siddiqa A, Jones DP, et al. Tryptophan catabolism reflects disease
- 367 activity in human tuberculosis. JCI Insight. 2020;5(10).
- 11. Beger RD, Schmidt MA, Kaddurah-Daouk R. Current Concepts in
- 369 Pharmacometabolomics, Biomarker Discovery, and Precision Medicine. Metabolites.
- 370 2020;10(4).
- 12. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case
- definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803-812.
- 13. Marais BJ, Heemskerk AD, Marais SS, et al. Standardized Methods for Enhanced
- 374 Quality and Comparability of Tuberculous Meningitis Studies. Clin Infect Dis.
- 375 2017;64(4):501-509.
- 14. Smith AGC, Gujabidze M, Avaliani T, et al. Clinical outcomes among patients with
- 377 tuberculous meningitis receiving intensified treatment regimens. Int J Tuberc Lung Dis.
- 378 2021;25(8):632-639.
- 15. Dian S, Ganiem AR, van Laarhoven A. Central nervous system tuberculosis. Curr
- 380 Opin Neurol. 2021;34(3):396-402.
- 16. Peloquin C. The Role of Therapeutic Drug Monitoring in Mycobacterial Infections.
- 382 Microbiol Spectr. 2017;5(1).
- 17. Haddad N, Carr M, Balian S, et al. The Blood-Brain Barrier and
- 384 Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of
- 385 Central Nervous System Infections in Adults. Antibiotics (Basel). 2022;11(12).
- 18. Ding J, Thuy Thuong Thuong N, Pham TV, et al. Pharmacokinetics and
- 387 Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis.
- 388 Clin Pharmacol Ther. 2020;107(4):1023-1033.

- 19. Dian S, Yunivita V, Ganiem AR, et al. Double-Blind, Randomized, Placebo-
- 390 Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for
- 391 Tuberculous Meningitis. Antimicrob Agents Chemother. 2018;62(12).
- 392 20. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and
- 393 pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
- 394 Antimicrob Agents Chemother. 2011;55(7):3244-3253.
- 395 21. Gleeson LE, Sheedy FJ, Palsson-McDermott EM, et al. Cutting Edge:
- 396 Mycobacterium tuberculosis Induces Aerobic Glycolysis in Human Alveolar
- 397 Macrophages That Is Required for Control of Intracellular Bacillary Replication. J
- 398 Immunol. 2016;196(6):2444-2449.
- 22. Olson GS, Murray TA, Jahn AN, et al. Type I interferon decreases macrophage
- 400 energy metabolism during mycobacterial infection. Cell Rep. 2021;35(9):109195.
- 401 23. Soltow QA, Strobel FH, Mansfield KG, Wachtman L, Park Y, Jones DP. High-
- 402 performance metabolic profiling with dual chromatography-Fourier-transform mass
- 403 spectrometry (DC-FTMS) for study of the exposome. Metabolomics. 2013;9(1
- 404 Suppl):S132-143.
- 405 24. Go YM, Walker DI, Liang Y, et al. Reference Standardization for Mass Spectrometry
- and High-Resolution Metabolomics Applications to Exposome Research. Toxicol Sci.
- 407 2015;148(2):531-542.
- 408 25. Yu T, Park Y, Johnson JM, Jones DP. apLCMS--adaptive processing of high-
- resolution LC/MS data. Bioinformatics (Oxford, England). 2009;25(15):1930-1936.

- 410 26. Uppal K, Soltow QA, Strobel FH, et al. xMSanalyzer: automated pipeline for
- 411 improved feature detection and downstream analysis of large-scale, non-targeted
- 412 metabolomics data. BMC Bioinformatics. 2013;14:15.
- 413 27. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses
- for RNA-sequencing and microarray studies. Nucleic acids research. 2015;43(7):e47.
- 415 28. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance
- 416 testing. Statistics in medicine. 1990;9(7):811-818.
- 417 29. Nagelkerke NJD. A note on a general definition of the coefficient of determination.
- 418 Biometrika. 1991;78(3):691-692.
- 419
- 420
- 421
- 422
- 423
- 424
- 425
- 426
- 427
- 428
- 429
- 429
- 430
-
- 431
- 432

433 Tables and Figure Legends (Figure files submitted separately)

434 Table 1

	TB meningitis (n=17)
Age, median (IQR)	36 (31-44)
Female sex, n (%)	9 (53)
TB meningitis diagnostic category, n (%)	
Definite (microbiologically confirmed)	5 (29)
Probable	3 (18)
Possible	9 (53)
CSF total WBC, median (IQR)	209 (130-286)
% Lymphocytes, median (IQR)	94 (85-96)
% Neutrophils, median (IQR)	5 (2-8)
TB meningitis grade, n (%)	
Grade 1	8 (47)
Grade 2	9 (53)
Grade 3	0 (0)

444 Figure 1 – Boxplots depicting median cerebrospinal fluid concentrations of anti-TB 445 antibiotics 2 hours after the most recent antibiotic dose for 17 study participants: (A) cycloserine, (B) ethambutol, (C) imipenem, (D) isoniazid, (E) levofloxacin, (F) linezolid, 446 447 (G) moxifloxacin, (H) pyrazinamide, and (I) rifampin. 448 Figure 2 – Boxplots depicting median cerebrospinal fluid concentrations of anti-TB 449 450 antibiotics 6 hours after the most recent antibiotic dose for 17 study participants: (A) 451 cycloserine, (B) ethambutol, (C) imipenem, (D) isoniazid, (E) levofloxacin, (F) linezolid, (G) moxifloxacin, (H) pyrazinamide, and (I) rifampin. 452 453 Figure 3 – Scatter plots with fitted regression lines depicting the relationship between 454 455 serum and cerebrospinal fluid concentrations of anti-TB drugs: (A) cycloserine, (B) 456 isoniazid, (C) linezolid, (D) pyrazinamide, (E) levofloxacin, (F) rifampin, (G) 457 moxifloxacin, (H) imipenem, and (I) ethambutol. For each figure, r represents the correlation coefficient with corresponding p-value. The adjusted R² was calculated using 458 a mixed effects linear model, adjusting for sampling time (2 or 6 hours), with p-values 459 derived from the pairwise comparison of models including and excluding the serum 460 concentration of each drug. 461 462 463 464 465

Figure 4 – Scatter plots with fitted regression lines depicting the relationship between

- 467 cerebrospinal fluid concentrations of anti-TB drugs and their mass spectrometry
- 468 intensity value as measured on the untargeted metabolomics platform: (A) ethambutol,
- (B) isoniazid, (C) linezolid, (D) imipenem, (E) pyrazinamide, (F) moxifloxicin, (G)
- 470 rifampin, and (H) levofloxacin. For each figure, r and p values are based on the Pearson
- 471 correlation coefficient for each drug.
- 472
- 473 **Figure 5 –** The bubble plots represent the adjusted R^2 values measuring the
- 474 association between anti-TB drug concentrations and soluble immune mediators
- 475 (metabolites, cytokines, and chemokines) in the cerebrospinal fluid. The color scale for
- each dot represents the adjusted R^2 value and dot size represents the $-\log P$ value for
- 477 each association.







 \triangleleft

ב



 \triangleleft

